The effect of
6-aminonicotinamide on the metabolism of RIF-1
tumor cells was investigated using 13C and 31P NMR spectroscopy.
6-Aminonicotinamide can be metabolized to 6-amino-NAD(P), a competitive inhibitor of
NAD(P)-requiring processes. 40 microM
6-aminonicotinamide led to an inhibition of
6-phosphogluconate dehydrogenase and an accumulation of
6-phosphogluconate. A subsequent accumulation of the
6-phosphogluconate precursor 6-phosphoglucono-delta-lactone was observed in the 13C NMR spectrum. These metabolites were shown to be intracellular, although a small amount of leakage of 6-phosphoglucono-delta-lactone occurred. The intracellular concentrations of
6-phosphogluconate and 6-phosphoglucono-delta-lactone were 1.9 +/- 0.8 micromol/108 cells (+/-1 standard deviation) and 0.8 +/- 0.4 micromol/10(8) cells, respectively, after 15 h.
Glucose utilization and
lactate production were significantly inhibited by
6-aminonicotinamide (both p < 0.05), indicating inhibition of glycolysis. 31P NMR data showed that
phosphocreatine was significantly depleted in cells exposed to
6-aminonicotinamide (p < 0.05). Exposure of RIF-1 cells to
6-aminonicotinamide prior to 3- or 6-Gy x-irradiation induced a supra-additive cell kill, indicating that
6-aminonicotinamide is acting as a radiosensitizer. There was no effect of
6-aminonicotinamide alone or when the
drug was given postradiation, suggesting that its mechanism of action may be by inhibition of radiation-induced repair.